| Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1-and OATP1B3-expressing HeLa cells NR Monks, S Liu, Y Xu, H Yu, AS Bendelow, JA Moscow Molecular cancer therapeutics 6 (2), 587-598, 2007 | 208 | 2007 |
| Anticancer, antichemotactic and antimicrobial activities of marine sponges collected off the coast of Santa Catarina, southern Brazil NR Monks, C Lerner, AT Henriques, FM Farias, EES Schapoval, ... Journal of Experimental Marine Biology and Ecology 281 (1-2), 1-12, 2002 | 143 | 2002 |
| Blocking anti‐apoptosis as a strategy for cancer chemotherapy: NF‐κB as a target NR Monks, DK Biswas, AB Pardee Journal of cellular biochemistry 92 (4), 646-650, 2004 | 85 | 2004 |
| Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris M Mooney, J Bond, N Monks, E Eugster, D Cherba, P Berlinski, ... PloS one 8 (4), e61088, 2013 | 75 | 2013 |
| Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue DJ Monsma, NR Monks, DM Cherba, D Dylewski, E Eugster, H Jahn, ... Journal of translational medicine 10, 1-18, 2012 | 75 | 2012 |
| Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors MJ Sale, E Minihane, NR Monks, R Gilley, FM Richards, KP Schifferli, ... Nature communications 10 (1), 5167, 2019 | 63 | 2019 |
| Oncolytic VSV primes differential responses to immuno-oncology therapy NM Durham, K Mulgrew, K McGlinchey, NR Monks, H Ji, R Herbst, ... Molecular Therapy 25 (8), 1917-1932, 2017 | 58 | 2017 |
| Anti-tumour screening of Brazilian plants NR Monks, SAL Bordignon, A Ferraz, KR Machado, DH Faria, RM Lopes, ... Pharmaceutical Biology 40 (8), 603-616, 2002 | 49 | 2002 |
| In vitro cytotoxicity of extracts from Brazilian Asteraceae NR Monks, A Ferraz, S Bordignon, KR Machado, MFS Lima, AB Rocha, ... Pharmaceutical biology 40 (7), 494-500, 2002 | 44 | 2002 |
| Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms DJ Monsma, DM Cherba, EE Eugster, DL Dylewski, PT Davidson, ... American Journal of Cancer Research 5 (4), 1507, 2015 | 41 | 2015 |
| Antitumor activity of MEDI3726 (ADCT-401), a pyrrolobenzodiazepine antibody–drug conjugate targeting PSMA, in preclinical models of prostate cancer S Cho, F Zammarchi, DG Williams, CEG Havenith, NR Monks, P Tyrer, ... Molecular Cancer Therapeutics 17 (10), 2176-2186, 2018 | 34 | 2018 |
| DNA interstrand cross-linking and TP53 status as determinants of tumour cell sensitivity in vitro to the antibody-directed enzyme prodrug therapy ZD2767 NR Monks, DC Blakey, SJ East, RI Dowell, JA Calvete, NJ Curtin, CE Arris, ... European Journal of Cancer 38 (11), 1543-1552, 2002 | 33 | 2002 |
| Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition A Daily, NR Monks, M Leggas, JA Moscow Toxicon 55 (4), 827-837, 2010 | 32 | 2010 |
| Melanoma genotypes and phenotypes get personal JM Pimiento, EM Larkin, KSM Smalley, GL Wiersma, NR Monks, ... Laboratory Investigation 93 (8), 858-867, 2013 | 28 | 2013 |
| Sensitivity of breast cancer cell lines to recombinant thiaminase I S Liu, NR Monks, JW Hanes, TP Begley, H Yu, JA Moscow Cancer chemotherapy and pharmacology 66, 171-179, 2010 | 28 | 2010 |
| Using a rhabdomyosarcoma patient‐derived xenograft to examine precision medicine approaches and model acquired resistance DJ Monsma, DM Cherba, PJ Richardson, S Vance, S Rangarajan, ... Pediatric blood & cancer 61 (9), 1570-1577, 2014 | 27 | 2014 |
| Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling JM Foley, DJ Scholten II, NR Monks, D Cherba, DJ Monsma, P Davidson, ... Journal of Translational Medicine 13, 1-12, 2015 | 25 | 2015 |
| Targeting the NF‐κB pathway in estrogen receptor negative MDA‐MB‐231 breast cancer cells using small inhibitory RNAs NR Monks, AB Pardee Journal of cellular biochemistry 98 (1), 221-233, 2006 | 24 | 2006 |
| Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue NR Monks, DC Blakey, NJ Curtin, SJ East, A Heuze, DR Newell British journal of cancer 85 (5), 764-771, 2001 | 20 | 2001 |
| Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors JD Peacock, D Cherba, K Kampfschulte, MK Smith, NR Monks, CP Webb, ... Journal of Translational Medicine 11, 1-13, 2013 | 18 | 2013 |
